NCT04737967 - The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

August 15, 2021

Study Completion Date

October 1, 2021

Conditions

Oncology PainChemotherapy-induced Peripheral Neuropathy

Interventions

DRUG

Venlafaxine

Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)

DRUG

Memantine

Patients will receive memantine (10 mg) once daily (Morel et al., 2016)

Trial Locations (1)

RECRUITING

Faculty of Medicine Cairo University - Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine, Cairo